Quercetin in Coronary Artery By-pass Surgery

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT04907253

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04907253
Other papers using this trial's data
  • Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients Aging cell, 2025-08 DOI, PubMed 40375481, PMC12341813 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04907253. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-04 (actual); primary completion 2023-12-01 (actual). Results posted on 2026-04-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Quercetin in Coronary Artery By-pass Surgery
Acronym
Q-CABG
Intervention (Drug)
Quercetin
Intervention (Drug)
Placebo
Lead sponsor
Montreal Heart Institute (class: other)

Record details

Record id
cardio:ct-nct04907253
Content hash
7b32af5844baaab1c7a06c3ca0ca4fb76787a33e6cbef132b275f2cd91af0516